Dyne Therapeutics CFO Erick Lucera Sells $33.5K of Stock
Erick Lucera, CFO, sold 1,991 shares of Dyne Therapeutics, Inc. at $16.82 a share, worth $33.5K in total on Nov 13, 2026. Shares held after the trade: 117,775 (-1.7%).
Dyne Therapeutics reported Q3 2026 financial results, highlighting a cash position of $684.1 million to support operations into late 2026. The company is preparing for a potential Q1 2027 U.S. launch of z-rostudirsen for DMD, which is currently under FDA priority review with a PDUFA date of January 21, 2027.
Term
Q3 2026
“As we work toward potential commercialization, we are investing across multiple programs with the goal of unlocking the full value of our FORCE platform. This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027.”
John Cox, president and chief executive officer of Dyne
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on muscle diseases using its proprietary FORCE platform. As of October 30, 2026, the company had 187,386,963 shares of common stock outstanding and expects to require substantial additional funding to advance its product candidates, which are not anticipated to reach commercialization until at least 2027.
Dyne Therapeutics Director Brian S. Posner Buys $40K of Stock
Brian S. Posner, Director, bought 2,500 shares of Dyne Therapeutics, Inc. at $16.00 a share, worth $40K in total on Oct 2, 2026. Shares held after the trade: 27,000 (+10.2%).
Dyne Therapeutics announced additional one-year clinical data from the Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), showing sustained functional improvement in myotonia, strength, and mobility. The data showed a 3.6-second relative improvement in hand myotonia at 6 months compared to placebo and divergence from a matched natural history cohort at 12 months. The company remains on track to report topline data from its registrational expansion cohort in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.